Alnylam Pharmaceuticals, Inc. (ALNY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es Yvonne L. Greenstreet.
ALNY tiene fecha de IPO 2004-06-01, 2,230 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $45.01B.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel RNAi (RNA interference) therapeutics for genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company has three marketed products: ONPATTRO for hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Alnylam maintains a robust pipeline of investigational therapies addressing hemophilia, hypertension, hypercholesterolemia, and metabolic liver disease, supported by strategic collaborations with Regeneron Pharmaceuticals and Sanofi Genzyme. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company has established multiple license and collaboration agreements with leading pharmaceutical organizations to advance RNAi-based drug development.
